Cargando…

p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer

Administration of the microtubule inhibitor docetaxel is a common treatment for metastatic castration-resistant prostate cancer (mCRPC) and results in prolonged patient overall survival. Usually, after a short period of time chemotherapy resistance emerges and there is urgent need to find new therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gruber, Martina, Ferrone, Lavinia, Puhr, Martin, Santer, Frédéric R, Furlan, Tobias, Eder, Iris E, Sampson, Natalie, Schäfer, Georg, Handle, Florian, Culig, Zoran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040497/ https://www.ncbi.nlm.nih.gov/pubmed/31951590 http://dx.doi.org/10.1530/ERC-19-0488

Ejemplares similares

The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells
por: Gruber, Martina, et al.
Publicado: (2019)

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells
por: Puhr, Martin, et al.
Publicado: (2014)

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy
por: Santer, Frédéric R., et al.
Publicado: (2015)

Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
por: Culig, Zoran, et al.
Publicado: (2012)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα(2) through IRF9
por: Erb, Holger H H, et al.
Publicado: (2013)

The role of epithelial–mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel‐resistant prostate cancer
por: Hanrahan, Karen, et al.
Publicado: (2017)

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer
por: Hoefer, Julia, et al.
Publicado: (2014)

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
por: Santer, Frédéric R, et al.
Publicado: (2010)

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
por: Kroon, Jan, et al.
Publicado: (2016)

Interleukin‐4 induces a CD44(high)/CD49b(high) PC3 subpopulation with tumor‐initiating characteristics
por: Erb, Holger H.H., et al.
Publicado: (2018)

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
por: Vakhrusheva, Olesya, et al.
Publicado: (2022)

Akacid Medical Formulation Induces Apoptosis in Myeloid and Lymphatic Leukemic Cell Lines In Vitro and In Vivo
por: Neuwirt, Hannes, et al.
Publicado: (2015)

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
por: Drápela, Stanislav, et al.
Publicado: (2020)

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
por: Oh, Su Jung, et al.
Publicado: (2012)

Inhibition of Nox4‐dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal‐mediated protumorigenic interactions
por: Sampson, Natalie, et al.
Publicado: (2018)

Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1
por: Hong, Xiaohong, et al.
Publicado: (2020)

Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells
por: Montagnani Marelli, Marina, et al.
Publicado: (2023)

Functionalized Lipid Nanocarriers for Simultaneous Delivery of Docetaxel and Tariquidar to Chemoresistant Cancer Cells
por: Kim, Chang Hyun, et al.
Publicado: (2023)

Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells
por: Weber, Anja, et al.
Publicado: (2018)

Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer
por: Pichler, Renate, et al.
Publicado: (2016)

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer
por: Puhr, M, et al.
Publicado: (2016)

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling
por: Nappo, G, et al.
Publicado: (2017)

Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis
por: Vinod, B S, et al.
Publicado: (2015)

Enhanced Inhibition of Prostate Tumor Growth by Dual Targeting the Androgen Receptor and the Regulatory Subunit Type Iα of Protein Kinase A in Vivo
por: Eder, Iris E., et al.
Publicado: (2013)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
por: Culig, Zoran
Publicado: (2021)

ZNF300 promotes chemoresistance and aggressive behaviour in non‐small‐cell lung cancer
por: Yu, Shilong, et al.
Publicado: (2020)

TFAP2C-Activated MALAT1 Modulates the Chemoresistance of Docetaxel-Resistant Lung Adenocarcinoma Cells
por: Chen, Jing, et al.
Publicado: (2019)

Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture
por: Eder, Theresa, et al.
Publicado: (2016)

miR-1205/DNAJB1 reverses docetaxel chemoresistance in human triple negative breast carcinoma cells via regulation of mutp53/TAp63 signaling: miR-1205/DNAJB1 reverses docetaxel chemoresistance in TNBC
por: Yin, Yongxiang, et al.
Publicado: (2021)

Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein
por: Wu, Dapeng, et al.
Publicado: (2017)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells
por: Chen, Jing, et al.
Publicado: (2016)

Use of miR-145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer
por: Zhu, Jin, et al.
Publicado: (2021)

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
por: Erb, Holger H. H., et al.
Publicado: (2020)

Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells
por: Ippolito, Luigi, et al.
Publicado: (2016)

Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer
por: Niu, Xiao-Bing, et al.
Publicado: (2017)

Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells
por: Feiersinger, Gertrud E., et al.
Publicado: (2018)

DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells
por: Lee, Yu-Hsien, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nobabco6hjbon845cv3209ukmm